DMT: The Spirit Molecule

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Retrieved on: 
星期二, 八月 8, 2023
Molecule, Neuron, Rat, DMT, CSE, DMT: The Spirit Molecule, Depression, Neuroplasticity, Stroke, Clinical trial, Penile spines, AGN, Pharmacokinetics, Brain, Biomarker, Signal transduction, Plasma, Ethics, Patient, Growth, Diagnosis, BDNF, Death, Imperial College London, CHDR, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.
  • The Phase 2 human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • Algernon consultant Dr. Rick Strassman, DMT research pioneer and author of the books DMT: The Spirit Molecule and The Psychedelic Handbook commented: “I am encouraged by the results of Algernon’s Phase 1 study in which a prolonged infusion of DMT achieved the desired pharmacokinetics.
  • “We are investigating DMT as a potential new therapeutic treatment that could have a positive impact on ischemic stroke patients worldwide.”

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Retrieved on: 
星期一, 六月 5, 2023
Molecule, Neuron, DMT, CSE, DMT: The Spirit Molecule, Stroke, Penile spines, AGN, Pharmacokinetics, Dendrite, Brain, Research, TBI, Trial of the century, Plasma, Dendritic spine, Traumatic brain injury, Synapse, BDNF, Safety, Pharmaceutical industry

AGN Neuro is the world’s first company to investigate DMT for both the treatment of stroke and traumatic brain injury (TBI).

Key Points: 
  • AGN Neuro is the world’s first company to investigate DMT for both the treatment of stroke and traumatic brain injury (TBI).
  • AGN Neuro is the first company to test DMT at single escalating concentrations with an IV dose for a 6-hour duration.
  • AGN Neuro has now established a single dose regimen which can now be used in its first Phase 2 study for stroke and TBI.
  • “Now that we have established the safety of a single sub psychedelic dose of DMT, we are planning to accelerate our DMT Phase 2 studies accordingly, for both stroke and TBI.”

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

Retrieved on: 
星期五, 十月 14, 2022
Molecule, LSD, Chronic cough, N,N-Dimethyltryptamine, Chronic kidney disease, DMT, Stroke, Science, IPF, Animal, Policy, Ethics, Family, DMT: The Spirit Molecule, Patient, Drug development, Brain, Music, Leiden University Medical Center, AGN, Neurogenesis, Trial of the century, Company, Ketamine, Industry, Constraint-induced movement therapy, CSE, Rehabilitation, Psilocybin, GLOBE, Clinical trial, Keynote, Pharmacy, Human, Pharmaceutical industry

Algernon recently announced that it became the Headline Sponsor for the Wonderland conference to be held in Miami from November 3rd to the 5th, 2022.

Key Points: 
  • Algernon recently announced that it became the Headline Sponsor for the Wonderland conference to be held in Miami from November 3rd to the 5th, 2022.
  • Algernon is very fortunate to have Dr. Rick Strassman as a key opinion leader on our DMT stroke research program, said Moreau.
  • Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs.
  • Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Retrieved on: 
星期一, 九月 12, 2022
Molecule, Leiden University Medical Center, Leiden University, Time, Safety, Trial of the century, Human, Ethics, Ketamine, University, LSD, DMT: The Spirit Molecule, Dream, Neurology, Company, Imperial College London, CHDR, Psilocybin, Growth, LUMC, Partnership, Stroke, Leiden Bio Science Park, Psychosis, IVF, Patient, Clinical trial, CSE, N,N-Dimethyltryptamine, AGN, Neurogenesis, Consciousness, Heart, Niacin, Pharmacokinetics, Pharmacy, Rehabilitation, GLOBE, DMT, Animal, Constraint-induced movement therapy, GMP, Brain, Pharmaceutical industry

Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study.

Key Points: 
  • Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study.
  • Christopher J. Moreau CEO of Algernon Pharmaceuticals further commented saying, We look forward to getting our DMT clinical stroke program started with our Phase 1 study at CHDR in the Netherlands, said.
  • Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke.
  • The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.